DESCRIPTIVE ANALYSIS OF THE CARFILZOMIB TOXICITY PROFILE IN PATIENTS WITH MULTIPLE MYELOMA. EXPERIENCE IN A THIRD LEVEL CENTER

被引：0
|
作者：
Gutierrez Lopez de Ocariz, X. [1 ]
Cuellar Perez-Avila, C. [1 ]
Zamanillo Herreros, I [1 ]
Iniguez Garcia, R. [1 ]
Poza Santaella, M. [1 ]
Alonso Fernandez, R. [1 ]
Sanchez Pina, J. M. [1 ]
Gonzalez Medina, J. [1 ]
Buenaventura Buendia, B. [1 ]
De Nicolas Sol, R. [1 ]
Vera Guerrero, E. [1 ]
Hidalgo Soto, M. [1 ]
Lopez Munoz, N. [1 ]
Lahuerta Palacios, J. J. [1 ]
Martinez Lopez, J. [1 ]
机构：
[1] Hosp Univ Octubre, Madrid, Spain
来源：
HAEMATOLOGICA | 2019年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO-020
引用
收藏
页码：201 / 202
页数：2
相关论文
共 50 条
  • [41] Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience
    Zherebtsova, Vera A.
    Vorobyev, Vladimir, I
    Gemdzhian, Eduard G.
    Ulyanova, Margarita A.
    Chernikov, Mikhail, V
    Ivanova, Valentina L.
    Vinogradova, Olga Yu
    Ptushkin, Vadim V.
    TERAPEVTICHESKII ARKHIV, 2021, 93 (07) : 785 - 792
  • [42] EFFICACY AND SAFETY OF THE TREATMENT WITH LENALIDOMIDE IN LONG TERM IN PATIENTS WITH MULTIPLE MYELOMA. EXPERIENCE OF A CENTRE
    Saucedo Alejandro, Marin
    Ana, Sanchez
    Pablo, Rios
    Joaquin, Brena
    Cristina, Notario
    Hector, Gonzalez
    Ana, Cabello
    Carmen, Marrero
    Nuria, Hernanz
    Ana, Oliva
    Antonio, Leon
    Mario, Rios
    Alexander, Figueroa
    Patricia, Hernandez
    Yaxiraxi, Lorenzo
    Maria Carmen, Mesa
    HAEMATOLOGICA, 2016, 101 : 305 - 305
  • [43] Phase I/II study of carfilzomib plus melphalan-prednisone (CMP) in elderly patients with de novo multiple myeloma.
    Kolb, Brigitte
    Hulin, Cyrille
    Caillot, Denis
    Benboubker, Lotfi
    Tiab, Mourad
    Blin, Nicolas
    Leleu, Xavier
    Roussel, Murielle
    Attal, Michel
    Facon, Thierry
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Infectious Complications in the Outpatient and Inpatient Autologous Stem Cell Transplantation Setting for Patients with Multiple Myeloma. Princess Margaret Cancer Center Experience
    Nikonova, Anna
    Zeglinski, Christina
    Husain, Shahid
    So, Miranda
    Atenafu, Eshetu G.
    Reece, Donna E.
    Trudel, Suzanne
    Kukreti, Vishal
    Tiedemann, Rodger E.
    Prica, Anca
    Franke, Norman Anthony
    Jane Huynh
    Tao, Leeping
    Chen, Christine I.
    BLOOD, 2018, 132
  • [45] Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Elderly Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis
    Facon, Thierry
    Moreau, Philippe
    Martin, Thomas G.
    Spicka, Ivan
    Oriol, Albert
    Koh, Youngil
    Lim, Andrew
    Mikala, Gabor
    Rosinol, Laura
    Yagci, Munci
    Cavo, Michele
    Yong, Kwee
    Risse, Marie-Laure
    Asset, Gaelle
    Schwab, Sandrine
    Martinez, Gracia
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S420 - S420
  • [46] EARLY DEATH IN MULTIPLE MYELOMA. ANALYSIS OF PATIENTS IN REAL-WORLD PRACTICE
    Lakhwani Lakhwani, S.
    Hernandez Garcia, M. T.
    Lorenzo Barreto, P.
    Cabrera Brito, D.
    Fernandez Gonzalez, M.
    Diaz Gomez, M.
    Raya Sanchez, J. M.
    HAEMATOLOGICA, 2019, 104 : 14 - 15
  • [47] Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
    Facon, Thierry
    Moreau, Philippe
    Martin, Thomas G.
    Spicka, Ivan
    Oriol, Albert
    Koh, Youngil
    Lim, Andrew
    Mikala, Gabor
    Rosinol, Laura
    Yagci, Munci
    Cavo, Michele
    Yong, Kwee
    Risse, Marie-Laure
    Asset, Gaelle
    Schwab, Sandrine
    Martinez, Gracia
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (05) : 1020 - 1029
  • [48] Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR
    Dimopoulos, Meletios
    Siegel, David
    White, Darrell J.
    Boccia, Ralph
    Iskander, Karim S.
    Yang, Zhao
    Kimball, Amy S.
    Mezzi, Khalid
    Ludwig, Heinz
    Niesvizky, Ruben
    BLOOD, 2019, 133 (02) : 147 - 155
  • [49] BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE FOLLOWED BY AUTOLOGOUS TRANSPLANTATION AS FIRST LINE TREATMENT IN MULTIPLE MYELOMA. SINGLE CENTER EXPERIENCE
    Arguinano, J. M.
    Zudaire, M.
    Pena, E.
    Aoiz, I.
    Hamdi, M.
    Mateos, M.
    Ardaiz, M.
    Viguria, M.
    Rodriguez Calvillo, M.
    Gorosquieta, A.
    Sanchez Anton, M.
    Quispe, I.
    Arregui, P.
    Montoya, M.
    Garcia Ramirez, P.
    Alvarellos, M.
    HAEMATOLOGICA, 2015, 100 : 735 - 735
  • [50] ELOTUZUMAB LENALIDOMIDE AND DEXAMETHASONE IN FRAIL ELDERLY PATIENTS WITH RELAPSED MULTIPLE MYELOMA. A REAL LIFE EXPERIENCE
    De Padua, L.
    Carbone, A.
    Saltarelli, F.
    Gangemi, D.
    Andriani, A.
    HAEMATOLOGICA, 2019, 104 : 165 - 166
12345